Clinical Trials Logo

Adenocarcinomas clinical trials

View clinical trials related to Adenocarcinomas.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03215810 Completed - Clinical trials for Non-Small Cell Lung Cancer

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

Start date: October 11, 2017
Phase: Phase 1
Study type: Interventional

Investigators plan to study the safety, side effects, and benefits of tumor-infiltrating lymphocytes (TILs) when they are given with the drug nivolumab. Nivolumab is a type of immunotherapy - a drug that is used to boost the ability of the immune system to fight cancer, infection, and other diseases.

NCT ID: NCT01730118 Completed - Breast Cancer Clinical Trials

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing

Start date: March 4, 2013
Phase: Phase 1
Study type: Interventional

Background: - Human epidermal growth factor receptor 2 (HER2, also known as c-erbB2 or neu)/neu (HER2) is a tumor protein that appears in almost a third of breast cancers and in several other types of cancers such as colon, prostate and non-small cell lung. Tumors that overexpress HER2 can be associated with a more aggressive cancer, higher recurrence rates, and reduced survival rates. Researchers are testing a therapeutic cancer vaccine designed to stimulate the immune system to recognize HER2. The vaccine, called adenoviral transduced autologous human epidermal growth factor receptor (AdHER)/neu dendritic cell vaccine, is custom-made using an individual's own immune cells. These cells will be collected and used to produce the vaccine. Objectives: - To test the safety and effectiveness of AdHER2 vaccination. Eligibility: - Individuals at least 18 years of age who have HER2-expressing tumors. Design: - Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Imaging studies will also be performed. - Participants will have an apheresis procedure to collect immune cells to create the vaccine. - Participants will receive five doses of the vaccine at study Weeks 0, 4, 8, 16 and 24. - Participants will be monitored with physical exams, frequent blood tests and imaging studies.